


SUPPLEMENTARY DATA

Supplementary Table 1. Adverse Events (AE)

	Combination Therapy	Insulin Therapy	P-Value
Any AE (% of patients)	90	93	NS
Therapy Related AEs			
Hypoglycemia			
% of patients	66	91	<0.0001
Incidence rate (event/patient year)	2.3	6.6	<0.0001
Sever hypoglycemia (n)	0	1	
Ankle edema (%)	9.3	3.4	<0.01
Injection site reaction (%)	1.6	0	
Gastrointestinal (%)	31	9	<0.0001
Series AD			
CV events (n)	0	5	
Cancer (n)	0	1	
Fractures (n)	0	0	
Death (n)	0	1	


SUPPLEMENTARY DATA

Supplementary Figure 1. Qatar Study profile




SUPPLEMENTARY DATA

Supplementary Figure 2. Change in sulfonylurea dose through the study



SUPPLEMENTARY DATA

Supplementary Figure 3. the mean glargine and aspart dose in patients in the Insulin Therapy arm at 3, 6, 12 and 18 months



SUPPLEMENTARY DATA

Supplementary Figure 4. Change in HbA1c in subjects in the Combination Therapy group stratified based upon ethnicity.

